Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus infection in chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2018 clinical practice guideline

Craig E. Gordon, Marina C. Berenguer, Wahid Doss, Fabrizio Fabrizi, Jacques Izopet, Vivekanand Jha, Nassim Kamar, Bertram L. Kasiske, Ching Lung Lai, Jose M. Morales, Priti R. Patel, Stanislas Pol, Marcelo O. Silva, Ethan M. Balk, Amy Earley, Mengyang Di, Michael Cheung, Michel Jadoul, Paul Martin

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update reflects the major advances since the introduction of directacting antivirals (DAAs) in the management of HCV infection in the CKD population. Methods: The KDIGO work group tasked with developing the HCV and CKD guideline defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence previously summarized by the evidence review team. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to appraise the quality of evidence and rate the strength of the recommendations. Searches of the Englishlanguage literature were conducted through May 2017 and were supplemented with targeted searches for studies of DAA treatment and with abstracts from nephrology, hepatology, and transplantation conferences. A review process involving many stakeholders, subject matter experts, and industry and national organizations informed the guideline's final modification. Recommendation: The updated guideline comprises 66 recommendations. This synopsis focuses on 32 key recommendations pertinent to the prevention, diagnosis, treatment, and management of HCV infection in adult CKD populations.

Original languageEnglish (US)
Pages (from-to)496-504
Number of pages9
JournalAnnals of internal medicine
Volume171
Issue number7
DOIs
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus infection in chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2018 clinical practice guideline'. Together they form a unique fingerprint.

  • Cite this

    Gordon, C. E., Berenguer, M. C., Doss, W., Fabrizi, F., Izopet, J., Jha, V., Kamar, N., Kasiske, B. L., Lai, C. L., Morales, J. M., Patel, P. R., Pol, S., Silva, M. O., Balk, E. M., Earley, A., Di, M., Cheung, M., Jadoul, M., & Martin, P. (2019). Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus infection in chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2018 clinical practice guideline. Annals of internal medicine, 171(7), 496-504. https://doi.org/10.7326/M19-1539